Default company panoramic image
Epimedx 20logo 20  20square

EpimedX LLC

EpimedX is an early-stage biotechnology company developing novel Gene Regulation Therapy for treatment of sickle cell disease, beta-thalassemia and malaria.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Oklahoma City, OK, USA
  • Currency USD
  • Founded August 2011
  • Employees 5
  • Website

Company Summary

EpimedX LLC is an Oklahoma biotechnology company dedicated to finding, patenting, and developing effective treatment for major diseases including sickle cell disease (SCD), beta-thalassemia, malaria, diabetes, and other inflammatory diseases including cardiovascular and neurodegenerative disease, all of which can be treated by our proprietary Gene Regulation Therapy. The number affected by these diseases worldwide is close to one billion.


  • 9891caf2 0259 40d3 ae69 0cd0fb1aa973
    Founder & Chief Scientific Officer

    Dr. Broyles is also President of the Sickle Cell Cure Foundation, Inc., a 501c3 nonprofit research corporation founded 2006, is a pioneer in sickle cell research for over 40 years and is the Principal Investigator for the research patented as GRT.

  • Default avatar
    Robert A Floyd
    Founder & Chief Operations Officer

    Dr. Floyd previously founded and managed three companies (Centaur Pharmaceuticals, Otologic Pharmaceutics, and Oconos) and therefore has a wealth of experience in the biotechnology sector.

  • 0fb0388a e511 4b0c a83c 68658d79a3a2
    Member/Research Technician

    Mr. Roth has been involved in development of EdX-17 and Gene Regulation Therapy for sickle cell disease. He began working part-time in the laboratory of Dr. Broyles in 1999 as a high school student and has been a full-time Research Technician with the Sickle Cell Cure Foundation and EpimedX since inception. Mr. Roth has a BA in Chemistry from the University of Massachusetts Amherst.

  • Default avatar
    Gary W. Bricker, MA, CFP
    Chief Financial Officer

    Mr. Bricker is a twenty-three year veteran of USAID. He has directed the program budget for several public health projects, including HIV/AIDS treatments in Zambia.

  • Default avatar
    Visar Belegu, PhD
    Member/Senior Scientist

    Dr. Belegu is A Senior Research Scientist at the Kennedy Krieger Research Institute of Johns Hopkins Medical School and has over 12 years experience in sickle cell research.

  • Default avatar
    Carol D. Curtis, PhD
    R&D Project Manager

    Dr. Curtis joined EpimedX in 2013. She is involved in Proof-of-Concept testing and is responsible for managing all of the aspects of preclinical development of EdX-17. Dr. Curtis earned a PhD from the University of Illinois in 2009 and completed postdoctoral training at the Oklahoma Medical Research Foundation.

  • 93ff4909 ba8f 4921 84f8 ae89c1b70f24
    Accountant/Research Technician

    Mr. Floyd has worked with 4 start-up biotechnology companies and has more than a decade of experience in laboratory operations management. He is an experienced research technician and accomplished accounts manager. Mr. Floyd manages all aspects of day-to-day financial accounting for EpimedX. He has a BS in Science from Oklahoma City University.


  • Default avatar
    Jim McGoodwin, JD, general & business counsel; F R (Rusty) Denton, PhD, MBA, JD, patent lawyer

Previous Investors

  • Default avatar
    Robert A. Floyd, PhD